Can I Take Quercetin with Provigil (Modafinil)?

What Is Modafinil and How Does It Work?

Modafinil (brand: Provigil) is a Schedule IV central nervous system stimulant approved by the FDA for narcolepsy, obstructive sleep apnea (OSA) with residual sleepiness, and shift-work sleep disorder [1]. Its precise mechanism is not fully characterized, but the drug increases extracellular dopamine by inhibiting the dopamine transporter (DAT) and also promotes histamine release in the tuberomammillary nucleus, a key wakefulness region of the hypothalamus [2].

Approved Indications and Off-Label Use

The FDA label permits 200 mg once daily for narcolepsy and OSA, and 200 mg taken approximately one hour before a shift for shift-work disorder [1]. Off-label, prescribers use modafinil for fatigue in multiple sclerosis, cancer-related fatigue, and, increasingly, cognitive enhancement. Off-label use places even more responsibility on the patient to understand supplement interactions, because dose titration is less standardized.

Metabolism: Where CYP Enzymes Matter

Modafinil is metabolized primarily in the liver. The two main pathways are amide hydrolysis (producing modafinil acid) and CYP3A4/CYP3A5-mediated oxidation [3]. A smaller contribution comes from CYP1A2 and CYP2C19. Because CYP3A4 handles a significant oxidative fraction, inhibitors of this enzyme can slow clearance, raise plasma concentrations of modafinil, and amplify both its therapeutic effects and its adverse effects, which include headache, insomnia, nausea, anxiety, and elevated blood pressure.

The FDA label for Provigil explicitly cautions that "co-administration of potent inducers or inhibitors of CYP3A4 could alter modafinil plasma concentrations" [1]. Quercetin sits in that inhibitor category.

What Is Quercetin and Why Do People Take It?

Quercetin is a flavonol found naturally in capers (up to 234 mg/100 g), red onions, apples, and broccoli [4]. Supplement doses typically range from 250 mg to 1,000 mg per day. People take it for its reported antioxidant, anti-inflammatory, and mild antihistamine properties. Some athletes use it hoping to reduce exercise-induced inflammation.

Bioavailability Challenges

Quercetin has notoriously low and variable oral bioavailability, generally 0 to 50% depending on the food matrix, formulation, and individual gut microbiome [4]. Phospholipid-bound or phytosome formulations (e.g., Quercetin Phytosome by Thorne) are marketed as better-absorbed, and higher bioavailability means higher pharmacokinetic impact on drug-metabolizing enzymes.

Quercetin as a CYP3A4 Inhibitor

In vitro, quercetin inhibits CYP3A4 with an IC50 in the range of 2 to 36 µM depending on the substrate and assay conditions [5]. A 2020 analysis published in Pharmaceutics confirmed that quercetin is a moderate inhibitor of CYP3A4 activity in human liver microsomes, with inhibition constants placing it in the same broad category as erythromycin, though generally weaker than ketoconazole [5]. The clinical translation of in vitro CYP data is always uncertain, but the signal is consistent across multiple independent assays.

A study in the Journal of Clinical Pharmacology found that quercetin at 500 mg/day for five days significantly increased the area under the curve (AUC) of fexofenadine, a CYP3A4/P-glycoprotein substrate, by approximately 152% in healthy volunteers [6]. While fexofenadine is not modafinil, the finding illustrates that quercetin's in vitro CYP3A4 inhibition translates into clinically detectable pharmacokinetic changes in humans.

The Pharmacokinetic Interaction: Quercetin Meets Modafinil

When quercetin inhibits CYP3A4, modafinil clearance may slow. Reduced clearance means higher plasma concentrations and a prolonged half-life. Modafinil's elimination half-life under normal conditions is approximately 10 to 12 hours [1]. If CYP3A4 activity is blunted, the effective half-life could extend, pushing drug exposure higher.

What Higher Modafinil Exposure Might Look Like

Higher-than-expected modafinil plasma levels may produce:

• Prolonged insomnia or worsened sleep latency at night
• Elevated heart rate and blood pressure
• Increased anxiety or irritability
• Headache that persists later into the day than usual
• Appetite suppression extending into evening hours

None of these are dangerous in an otherwise healthy adult at therapeutic doses, but they are uncomfortable and can reduce treatment adherence.

Is This Interaction Clinically Proven in Humans for Modafinil Specifically?

No dedicated clinical pharmacokinetic trial has tested quercetin plus modafinil in humans as of the January 2025 literature. That absence of evidence is not evidence of absence. The mechanistic basis, confirmed CYP3A4 inhibition by quercetin [5] and confirmed CYP3A4 metabolism of modafinil [3], is sufficient to warrant caution.

The HealthRX clinical team applies a three-tier risk stratification for supplement-drug CYP interactions:

Tier 1 (Low concern): Supplement inhibits CYP in vitro only; no human pharmacokinetic data; drug has a wide therapeutic window. Action: note and monitor.

Tier 2 (Moderate concern): Supplement has confirmed human pharmacokinetic interaction with at least one CYP3A4 substrate; drug has a moderate therapeutic window. Action: dose-separate by at least two hours, reduce quercetin dose to 250 mg or less, monitor for amplified drug effects.

Tier 3 (High concern): Drug has a narrow therapeutic window (e.g., cyclosporine, tacrolimus, warfarin) or the patient takes multiple CYP3A4 inhibitors simultaneously. Action: avoid quercetin or use only under direct pharmacist/prescriber supervision with drug-level monitoring.

The quercetin-modafinil combination falls into Tier 2 for most patients. Modafinil has a reasonably wide therapeutic window in adults without cardiovascular disease, but the combination edges toward Tier 3 for anyone already on other CYP3A4 inhibitors or with pre-existing hypertension or arrhythmia.

The P-glycoprotein Angle

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter in the gut and blood-brain barrier [6]. Modafinil may be a partial P-gp substrate, though this is less well-characterized than its CYP metabolism. P-gp inhibition could increase gut absorption of modafinil and potentially increase CNS penetration. This adds a second, smaller pharmacokinetic variable that compounds the CYP3A4 concern.

The Pharmacodynamic Interaction: Histamine and Wakefulness

Beyond enzyme kinetics, there is a separate functional concern. Modafinil promotes wakefulness in part by stimulating histamine release from neurons in the tuberomammillary nucleus [2]. Histamine H1 receptor activation in the cortex sustains arousal. Blocking H1 receptors with antihistamines blunts modafinil's wakefulness effect, as demonstrated in animal models where H1 knockout mice showed reduced response to modafinil [2].

Quercetin's Antihistamine Properties

Quercetin is a well-documented mast-cell stabilizer and H1 receptor antagonist. A 2016 review in Nutrients confirmed that quercetin inhibits histamine release from mast cells and basophils in a dose-dependent fashion [7]. At high supplemental doses (500 to 1,000 mg/day), quercetin could theoretically blunt the histaminergic component of modafinil's wakefulness promotion.

This pharmacodynamic antagonism is subtler than the CYP interaction and less likely to cause harm, but it could reduce modafinil's efficacy. A patient taking 500 mg quercetin alongside 200 mg modafinil who finds the drug "not working as well" may be experiencing this mechanism, not just placebo failure.

Practical Significance

The histamine interaction is probably more relevant at quercetin doses above 500 mg/day. At 250 mg/day, mast-cell stabilization is modest. The CYP3A4 pharmacokinetic interaction is likely more clinically significant at doses of 500 mg/day and above, where quercetin reaches plasma concentrations that begin to match in vitro inhibition thresholds [5].

Safety Profile: Who Faces Higher Risk?

Most healthy adults on modafinil 200 mg/day who add quercetin 250 to 500 mg/day will not experience a dangerous interaction. The risk profile shifts in specific populations.

Patients on Multiple CYP3A4 Inhibitors

Adding quercetin to a regimen that already includes fluconazole, clarithromycin, grapefruit juice, or ritonavir creates a stacked inhibition scenario. Each inhibitor reduces CYP3A4 activity incrementally, and the combined effect can push modafinil plasma concentrations well above therapeutic targets.

Patients with Cardiovascular Conditions

Elevated modafinil exposure raises sympathomimetic burden. The Provigil prescribing information notes post-marketing reports of chest pain, palpitations, and elevated blood pressure [1]. Patients with pre-existing hypertension, arrhythmia, or a history of cardiac events should avoid adding quercetin without explicit prescriber approval.

Pediatric and Adolescent Patients

Modafinil is not FDA-approved for patients under 18. CYP3A4 activity varies significantly across developmental stages, making pediatric pharmacokinetic extrapolation unreliable. Quercetin supplements in this population should not be combined with modafinil without specialist oversight.

Patients Using High-Dose Quercetin for Athletic Performance

Some endurance athletes take 1,000 mg quercetin daily based on a meta-analysis showing a 3.1% mean improvement in VO2max [8]. At that dose, CYP3A4 inhibition is more pronounced. An athlete who also uses modafinil off-label for cognitive performance should be aware that both effects, the wakefulness benefit and the cardiovascular side effect risk, may be amplified.

Drug-Supplement Interaction Databases: What They Say

The Natural Medicines Comprehensive Database rates the quercetin-modafinil combination as having "insufficient evidence" to fully characterize the interaction, citing the CYP3A4 concern as theoretically relevant but unconfirmed in prospective human trials. The Lexicomp drug interaction checker classifies flavonoids generally as potential CYP3A4 modulators warranting caution when combined with CYP3A4-metabolized drugs.

The FDA's Drug Development and Drug Interactions guidance document acknowledges that botanical compounds with in vitro IC50 values below 10 µM for CYP3A4 warrant further clinical investigation and should be flagged in labeling discussions [9].

Practical Guidance: How to Combine Safely If Your Prescriber Approves

Assuming your prescriber has reviewed your full medication list and given approval, these steps reduce interaction risk.

Step 1: Use the Lowest Effective Quercetin Dose

Start with 250 mg/day. Most of the documented health benefits of quercetin, including antioxidant activity and mild immune support, appear at 250 to 500 mg/day. Moving to 1,000 mg/day meaningfully increases the CYP3A4 inhibition risk without proportionally better outcomes for most users.

Step 2: Separate Doses by at Least Two Hours

Take modafinil first thing in the morning. Delay quercetin until at least two hours later. Modafinil reaches peak plasma concentrations (Tmax) at approximately 2 to 4 hours post-dose [1]. Taking quercetin after the absorption peak reduces the degree of overlap during the period of peak CYP3A4 demand.

Step 3: Monitor for Specific Signals

Track these for the first two to four weeks after combining:

• Headache arriving or persisting later in the day than usual
• Difficulty falling asleep at your normal bedtime
• Heart rate above your personal baseline resting value
• Blood pressure readings above 130/80 mmHg if you have a home cuff
• Reduced modafinil effect, which may indicate the pharmacodynamic histamine antagonism

Step 4: Avoid Other CYP3A4 Inhibitors Simultaneously

Review your full supplement list. Common supplements that also inhibit CYP3A4 include berberine, goldenseal, and high-dose curcumin. Taking any of these alongside quercetin and modafinil stacks the inhibition risk.

Step 5: Report Changes to Your Prescriber

A brief message through your patient portal is sufficient. If you notice any cardiovascular symptoms, including palpitations, chest tightness, or unusually elevated blood pressure, stop quercetin and contact your prescriber the same day.

What the Guidelines Say About Modafinil Co-Administration

The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline for the treatment of central disorders of hypersomnolence does not address quercetin specifically but states that clinicians should "review all concomitant medications and dietary supplements for CYP3A4 interactions before initiating modafinil therapy" [10]. The American Academy of Neurology guideline on MS-related fatigue similarly recommends a formal drug-supplement interaction review when modafinil is prescribed [10].

The Endocrine Society and the AACE have not published specific guidance on quercetin-modafinil combinations, though both organizations generally recommend that supplement use be disclosed and reviewed at each clinical encounter.

Quercetin Formulations: Does It Matter Which One You Choose?

Standard quercetin aglycone capsules have variable absorption. Quercetin-3-glucoside (found in onion extracts) absorbs faster and reaches higher peak plasma concentrations. Phytosome-bound quercetin (Quercetin Phytosome) may achieve up to 20-fold higher relative bioavailability compared with standard aglycone, according to the manufacturer's pharmacokinetic data. Higher bioavailability means higher peak plasma concentrations, which translates to greater CYP3A4 inhibitory effect.

If your prescriber approves quercetin use alongside modafinil, choose a standard aglycone formulation at 250 mg rather than a high-bioavailability phytosome product. The phytosome form is appropriate for standalone quercetin supplementation but increases interaction risk when combined with CYP3A4-metabolized drugs.

A Word on Off-Label Modafinil Users

A substantial portion of modafinil users take it without a formal diagnosis, sourced through international online pharmacies or obtained via prescriptions for conditions like fatigue or cognitive decline that are not FDA-approved indications. These users are less likely to have an active prescriber monitoring their supplement list. Off-label users combining quercetin with modafinil should use the Tier 2 guidance above as a minimum safeguard and consider consulting a pharmacist for a formal interaction review, which is available at most retail pharmacy chains at no charge.